Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating,
Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
J.P. Morgan Remains a Buy on Boston Scientific (BSX)
In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Boston Scientific (BSX – Research Report), with a
Boston Scientific (NYSE:BSX) Price Target Raised to $115.00
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
MassDevice2d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
5BSX : Boston Scientific Clocks 22% Jump In Q4 Sales On Strong...
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
Boston Scientific remains bullish despite tariffs, with sales buoyed by Minnesota tech
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
FierceBiotech2d
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
Boston Scientific targets 12%-14% EPS growth for 2025 with strong FARAPULSE and WATCHMAN momentum
Q4 2024 Management View CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in ...